One enzyme, two changes, one rising level: a metabolism review from MN660's sixth unit traces clozapine through CYP1A2 after a composite patient quits smoking, then after fluvoxamine is added. Searches like "mn 660 unit 6 assignment example", "mn660 unit 6 sample" and "mn660 unit 6 example" land here.
One Enzyme, Two Levels: CYP1A2, Clozapine and Caffeine After a Man Stops Smoking
[Student Name]
Purdue University Global
MN660: PMHNP Neuroscience and Psychopharmacology
Unit 6 Assignment
[Instructor Name]
[Date]
Composite patient written as a model document. The regimen is bracketed; nothing here is a prescribing instruction, and any action is left to the prescriber.
The Case
A composite 34-year-old man with treatment-resistant schizophrenia has taken [clozapine, established dose] for four years, stable, with levels in range. He smoked 25 cigarettes a day. Today he enters a smoke-free residential program and stops smoking completely. His medications are unchanged. He drinks about four cups of coffee a day.
The Pathway
Clozapine is cleared mainly by hepatic CYP1A2, with smaller contributions from CYP3A4 and CYP2C19, to norclozapine and clozapine N-oxide. Because CYP1A2 carries most of the load, anything that changes that one enzyme changes clozapine exposure substantially.
Induction by Smoke
Polycyclic aromatic hydrocarbons in tobacco smoke activate the aryl hydrocarbon receptor, which increases the expression of CYP1A2 (Kroon, 2007). Smokers therefore clear clozapine faster and need higher doses to reach the same level. His four-year stable dose was set while he smoked. Enzyme: CYP1A2. Direction of change in its activity: up while smoking. Direction of change in clozapine: down. Time course: steady for years. Observable consequence: none, because the dose was set to match.
De-Induction When He Stops
When he stops smoking, induction fades as the extra enzyme is broken down and not replaced. Over roughly the following week or two, clearance falls and plasma clozapine rises substantially. In patients whose smoking changed, clozapine levels varied considerably with cigarette consumption (Haslemo et al., 2006). Enzyme: CYP1A2. Direction: activity down. Clozapine: up. Time course: rising over days, with the largest change in the first one to two weeks. Observable consequence: see below.
This interaction is the less intuitive of the two in this review and the one most often missed, because nothing is added to his medication list; something is taken away from his life.
Nicotine Replacement Does Not Prevent It
If he uses nicotine patches, the rise still happens. Nicotine is not the inducer; the hydrocarbons in smoke are (Kroon, 2007). Replacing nicotine without smoke leaves CYP1A2 activity falling.
A Second Scenario: Fluvoxamine Added
Suppose [fluvoxamine] were added for obsessive symptoms. Fluvoxamine is a strong CYP1A2 inhibitor and can raise clozapine exposure several-fold (Wetzel et al., 1998). Enzyme: CYP1A2. Direction: activity down, by inhibition. Clozapine: up, potentially much more than with smoking cessation. Time course: within days of starting fluvoxamine. Observable consequence: the same effects as below, possibly more severe.
Caffeine: The Same Enzyme, a Second Level
Caffeine is also cleared mainly by CYP1A2. As induction fades, his caffeine levels will rise too, even though he drinks the same four cups a day. He may feel jittery or sleep poorly, and caffeine can itself raise clozapine levels slightly by competing for the enzyme.
What Rising Levels Would Produce
Staff would likely notice sedation first, then drooling (hypersalivation), dizziness on standing (orthostasis), and constipation. A lowered seizure threshold is the most serious effect. These are expected consequences of higher clozapine exposure, and they would be most likely in the first two weeks after he stopped smoking.
Conclusion
Therapeutic drug monitoring exists partly for situations like this: a change in a patient's habits, not in his prescription, can change a drug level substantially. Any response, whether monitoring, a dose change or both, is left to his prescriber.
References
Haslemo, T., Eikeseth, P. H., Tanum, L., Molden, E., & Refsum, H. (2006). The effect of variable cigarette consumption on the interaction with clozapine and olanzapine. European Journal of Clinical Pharmacology, 62(12), 1049-1053. https://doi.org/10.1007/s00228-006-0209-9
Kroon, L. A. (2007). Drug interactions with smoking. American Journal of Health-System Pharmacy, 64(18), 1917-1921. https://doi.org/10.2146/ajhp060414
Wetzel, H., Anghelescu, I., Szegedi, A., Wiesner, J., Weigmann, H., Härtter, S., & Hiemke, C. (1998). Pharmacokinetic interactions of clozapine with selective serotonin reuptake inhibitors: Differential effects of fluvoxamine and paroxetine in a prospective study. Journal of Clinical Psychopharmacology, 18(1), 2-9. https://doi.org/10.1097/00004714-199802000-00002
How this MN660 Unit 6 example is structured
The case is given in four lines at the top, including the one detail that drives everything, his smoking history, and the regimen itself appears only as [clozapine, established dose] in brackets. Each interaction is then written in a fixed sequence: the enzyme, the direction of change in its activity, the direction of change in the drug's concentration, the approximate time course, and the observable consequence. That sequence answers the question this unit commonly poses before anyone can ask it. The smoking section precedes the fluvoxamine section because de-induction is the less intuitive of the two and the one most often missed. A short paragraph on caffeine, another CYP1A2 substrate, shows the same enzyme raising a second level in the same man. The conclusion notes that therapeutic drug monitoring exists partly for this reason and leaves any action to the prescriber. Label and review citations follow.
Get an MN660 Unit 6 example written to your instructions
Does your Unit 6 prompt supply the drug pair, or ask you to choose an interaction? Either suits this format. Include the case, the rubric and any required layout. The first review is free, written to those instructions and returned in 24-48h, with every interaction stated as enzyme, direction, concentration, timing and effect, and any regimen bracketed as a composite. The paper above is an original model document written by our desk, not a submitted student paper and not an official Purdue University Global document.
MN660 Unit 6 questions, answered
Should the review include specific plasma level targets?
Only as reported ranges from a cited source, and only if the prompt asks. Clozapine monitoring uses published reference ranges, and a review can note that such ranges exist and why they matter here. Advising what level a particular patient should reach, or how to adjust toward it, moves from pharmacology into management and is best left out.
How do I decide which enzyme is the main route?
Check the product label and a pharmacology reference, which usually state the primary and minor pathways. For clozapine, CYP1A2 is the major route, with lesser roles for CYP3A4 and CYP2C19. When references disagree about minor pathways, cite the one you used and focus the review on the pathway that carries the interaction you are explaining.
Is it enough to say a drug is an inhibitor?
Rarely. Say which enzyme it inhibits, how strongly by the usual classification, and which substrate level rises as a result. Naming an inhibitor but not its enzyme leaves the reader unable to predict anything, and that gap is among the most common reasons metabolism work in this course loses marks.